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A case–control study from Uganda found that the risk of Kaposi’s sarcoma increased with increasing titre of antibodies against
Kaposi’s sarcoma-associated herpesvirus (KSHV) latent nuclear antigens, independently of HIV infection. Clinically, widespread
Kaposi’s sarcoma was more frequent among patients with HIV infection than in those without, but was not related to anti-KSHV
antibody titres.
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The work described here was part of a large epidemiological study
of cancer in Uganda (Newton et al, 2001, 2002). The findings in
relation to Kaposi’s sarcoma in HIV-seronegative and seropositive
people and the seroepidemiology of Kaposi’s sarcoma-associated
herpesvirus (KSHV; human herpesvirus-8 (HHV-8)) are reported
elsewhere (Ziegler et al, 1997, 2003; Newton et al, 2003). We
examine here the role of antibodies against KSHV latent antigens
encoded by orf73 and HIV serostatus on the clinical features and
risk of Kaposi’s sarcoma in Ugandan adults. Some of the results
relating to anti-KSHV antibody titres and Kaposi’s sarcoma in
HIV-seronegative people have been published elsewhere (Ziegler
et al, 2003).
MATERIALS AND METHODS
Between 1994 and 1998, we recruited adults 15 years or older with
a new diagnosis of cancer from the wards and outpatient clinics of
the main hospitals in Kampala, Uganda. After informed consent
and counselling, patients were interviewed and tested for infection
with HIV-1 using the Cambridge Bioscience Recombigen ELISA
(Cambridge, MA, USA) on sera or the GACELISA method (Murex,
Dartford, UK) on saliva. The study was approved by the
Committee on Human Research (VA Medical Centre and
University of California San Francisco) and by the Uganda
National Council for Science and Technology.
In total, we recruited 669 cases with Kaposi’s sarcoma. Of these,
49% (331) had enough sera stored for anti-KSHV antibody testing
and 77% (518) were seen by a study doctor, who conducted a
clinical examination in which the physical location of tumour
lesions was recorded. Where detected, the presence of internal
lesions was also recorded. Cases were categorised according to
whether the Kaposi’s sarcoma lesions were clinically localised (i.e.,
restricted to just one area of the body, such as a limb, or an area of
the torso or face), or widespread (i.e., affecting more than one area
of the body). Cases with an internal lesion (e.g., oral, gastro-
intestinal or lung) were recorded as having widespread disease. For
297 cases with an assessment of the clinical stage of their disease at
diagnosis enough sera were available to test for antiKSHV
antibodies.
Controls comprised 306 people with non-malignant manifesta-
tions of HIV disease, recruited from the outpatient department of
Mulago Hospital and 723 patients with other malignancies or
benign tumours, for whom a stored blood sample was available for
KSHV testing. The latter group comprised people with cancers of
the oral cavity (28), oesophagus (37), stomach (20), liver (47), skin
(23), breast (68), cervix (180), ovary (20), prostate (11), penis (13),
eye (54), and non-Hodgkin’s lymphoma (44), Hodgkin’s disease
(24), other cancer sites or types (125) and benign tumours (29).
A single investigator (DB) performed the immunofluorescence
assays to detect antibodies against the latent nuclear antigen of
KSHV encoded by orf73 and was blinded to the case–control
status of the samples. Results were graded by fluorescent intensity Received 6 January 2003; revised 2 May 2003; accepted 7 May 2003
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yand are reported here as negative (o1:100), one plus, two plus
and three plus, indicating absent, weak, moderate and strong
fluorescent signals, respectively. The fluorescent signal intensity
was related to anti-KSHV antibody titre–the median titres were
1:800 for low-signal intensity (þ), 1:25600 for medium-signal
intensity (þþ) and 1:51200 for high-signal intensity (þþþ).
Further details of the testing procedure and scoring mechanism for
signal intensity are described elsewhere (Sitas et al, 1999).
Data were computerised by trained clerks using EPI-INFO
software and statistical analyses were conducted using STATA
(Dean et al, 1990; STATA, 2001). Odds ratios (ORs) were estimated
using unconditional logistic regression modelling with adjustment
for age group (o30, 30–44, 45þ) and sex. Tests for association
used the w
2 test on one degree of freedom (unless otherwise stated).
All P-values are two-sided.
RESULTS
The proportion of Kaposi’s sarcoma cases with widespread rather
than localised disease at diagnosis was higher in HIV-infected than
uninfected people (78% (337 out of 433) vs 36% (31 out of 85); w
2
(one degree of freedom (d. f.))¼ 32.9, Po0.001), but did not differ
according to the fluorescent signal intensity of anti-KSHV
antibodies either in HIV-seronegative (w
2 for trend¼3.7, P¼0.3)
or in HIV-seropositive people (w
2 for trend¼2.1, P¼0.6; Table 1).
Among controls, the seroprevalence of anti-KSHV antibodies
was 46% (476 out of 1029) and did not vary significantly between
the constituent subgroups of cancer sites or types and other
diseases (w
2 for heterogeneity (14 d.f.)¼21.9, P¼0.1; data not
shown). Anti-KSHV antibodies were present in 50% (302 out of
607) of HIV-seronegative controls and 41% (174/422) of HIV-
seropositive controls, but after adjustment for age and sex, there
was no significant association between infection with HIV and the
presence of anti-KSHV antibodies (w
2 (1d.f.)¼1.4, P¼0.2). Nor
was there any evidence that the fluorescent signal intensity, a
measure of the titre of anti-KSHV antibodies, differed significantly
between HIV-seropositive and -seronegative controls (w
2 for
trend¼2.3, P¼0.5; Table 2).
The seroprevalence of anti-KSHV antibodies among patients
with Kaposi’s sarcoma, was 81% (269 out of 331) and did not differ
significantly between those with and without concurrent HIV
infection (79% in HIV-seronegative vs 82% in -seropositive cases;
w
2 (1d.f.)¼1.8, P¼0.2). The OR for Kaposi’s sarcoma associated
with anti-KSHV antibodies was 3.8 in HIV-seronegative people
(95% confidence interval (CI) 2.1–6.8; Po0.001) and 6.3 in HIV-
seropositive people (95% CI 4.2–9.2; Po0.001). The risk increased
with increasing fluorescent signal intensity to anti-KSHV anti-
bodies both in HIV-seronegative (w
2 for trend¼29.7, Po0.001)
and -seropositive people (w
2 for trend¼106.1, Po0.001; Table 3).
DISCUSSION
Here, we show that the relative risk of Kaposi’s sarcoma increased
with increasing titre of antibodies against KSHV latent nuclear
Table 1 Distribution of anti-KSHV antibodies among those with Kaposi’s
sarcoma according to whether the patient had clinically widespread disease
or not,
a stratified by HIV serostatus
Clinically widespread disease (percentage/number)
No Yes
HIV seronegative
KSHV seronegative 50% (6) 50% (6)
KSHV seropositive 57% (30) 43% (23)
+ 70% (14) 30% (6)
++ 66% (12) 34% (6)
+++ 44% (4) 56% (5)
HIV seropositive
KSHV seronegative 31% (13) 69% (29)
KSHV seropositive 22% (43) 78% (151)
+ 18% (16) 82% (71)
++ 25% (22) 75% (65)
+++ 25% (5) 75% (15)
aA patient was defined as having clinically widespread disease if lesions occurred in
more than one area of the skin or if an internal (e.g., oral, lung, gastrointestinal tract)
lesion was present.
Table 2 Distribution of anti-KSHV antibodies among controls, stratified
by HIV serostatus
HIV seronegative HIV seropositive
KSHV seronegative 50% (305) 59% (248)
KSHV seropositive
+ 28% (167) 27% (114)
++ 17% (105) 11% (46)
+++ 5% (30) 3% (14)
Total 100% (607) 100% (422)
w
2 trend (1 d.f.)¼2.3, P¼0.5
a
aAdjusted for age and sex; d.f.¼degrees of freedom.
Table 3 Odds ratio (OR) for Kaposi’s sarcoma according to fluorescent signal intensity of anti-KSHV
antibodies, stratified by HIV serostatus
Cases Controls OR (95% CI) by titre
HIV Seronegative
KSHV seronegative 17 305 1.0
KSHV seropositive
+ 24 167 2.3 (1.2–4.7)
++ 27 105 5.7 (2.8–11.6)
+++ 12 30 7.1 (2.8–17.8)
w
2trend (1d.f.)¼29.7, Po0.001
HIV Seropositive
KSHV seronegative 45 248 1.0
KSHV seropositive
+ 88 114 4.1 (2.6–6.3)
++ 95 46 10.8 (6.6–17.8)
+++ 23 14 9.3 (4.3–20.2)
w
2trend (1d.f.)¼106.1, Po0.001
ORs adjusted for age and sex; d.f.¼degrees of freedom.
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The risk of Kaposi’s sarcoma is increased in people with HIV
infection and the disease tends to be more widespread and
aggressive than in those without (Buchbinder and Friedman-Kien,
1991). However, in these data, HIV infection is not related either to
the prevalence or to the titre of antibodies against KSHV latent
antigens. Furthermore, among people diagnosed with Kaposi’s
sarcoma, clinically widespread disease was associated with HIV
infection, but was not related to anti-KSHV antibody titres. We
cannot exclude the possibility of some misclassification of tumour
burden and the impact of this on our results is unclear.
Nonetheless, on the basis of these data, the effect of HIV infection
both on the risk and on the clinical presentation of Kaposi’s
sarcoma would seem to be unrelated to antibodies against KSHV
latent antigens.
In this study, we could not quantify the impact of HIV infection
specifically on the risk of Kaposi’s sarcoma because a special
emphasis had been placed on recruiting HIV-seronegative cases
(Ziegler et al, 2003). However, results presented here in relation to
KSHV antibody titres are in accord with those reported by Sitas
et al (1999) from a case – control study of black South African
cancer patients. Furthermore, in a cohort study of HIV-infected
men in Europe, Rezza et al (1999) showed that high titres of anti-
KSHV antibodies were predictive of the subsequent development
of Kaposi’s sarcoma among KSHV-infected individuals. These
prospective data, together with the fact that the clinical burden of
tumour lesions is independent of the titre of anti-KSHV antibodies
(Table 1), argue against the possibility that high titres of antibodies
against KSHV latent nuclear antigens result from the presence of
Kaposi’s sarcoma lesions. Presumably, the titre of antibodies
against KSHV reflects the number of circulating KSHV-infected
cells (i.e., the KSHV viral load), and that for a given titre, the
burden of infected cells is higher among HIV-infected individuals
than in those without HIV, and there is currently some evidence to
support this (Tedeschi et al, 2001).
Little is known of the determinants of high antibody titres in
individuals with anti-KSHV antibodies. In a previous report, we
showed that among people with antibodies to KSHV in Uganda,
the proportion with high titres increased with increasing age and
with a past history of blood transfusion (Newton et al, 2003).
Plancoulaine et al (2002) also showed that anti-KSHV antibody
titres increased with age and were higher in men than in women.
The determinants of high anti-KSHV antibody titres, their
relationship with KSHV viral load and their role in the aetiology
of Kaposi’s sarcoma warrant further investigation.
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The Uganda Kaposi’s Sarcoma Study Group includes named
authors and V Sembajwe, M Kalinaki, R Byansi, C Rwatooro,
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Bitamazire, E Katabira, J Mugerwa (deceased), D Tindyebwa, C
Ateenyi-Agaba, L Marum, J Whitworth, B Richardson, G Reeves
and K de Cock.
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